Plasma AR and abiraterone-resistant prostate cancer

Date: 
6 Nov 2015
Source: 
Science Translational Medicine
Audience: 
Professionals
Type of resource: 
Research

Androgen receptor targeting is the cornerstone of prostate cancer treatment. Even when the tumors become “castration-resistant” or no longer sensitive to androgen deprivation, androgen signaling can still be effectively targeted by newer drugs such as abiraterone and enzalutamide, which also inhibit the androgen signaling axis.